Valuation : MacroGenics, Inc.

Market Cap 275M 237M 223M 203M 379M 26.09B 381M 2.64B 1.02B 13.33B 1.03B 1.01B 42.43B P/E 2026 *
-2.77x
P/E 2027 * -2.63x
Enterprise Value 275M 237M 223M 203M 379M 26.09B 381M 2.64B 1.02B 13.33B 1.03B 1.01B 42.43B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 3.04x
Free-Float
96.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.82%
1 week+6.93%
Current month+8.27%
1 month+6.93%
3 months+11.34%
6 months+93.72%
Current year+168.32%
1 week 4.11
Extreme 4.11
4.49
1 month 3.78
Extreme 3.785
4.49
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
28.09
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 12/08/2025
Director of Finance/CFO 59 30/04/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 31/08/2001
Director/Board Member 53 12/08/2025
Director/Board Member 62 30/09/2004
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Sell

General Counsel

-31,105 0.0489%
17/08/26 Exercice

Chief Technology Officer

80,000 0.1259%
19/05/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%+6.93%+145.45%-15.62% 280M
+2.02%+1.26%+41.37%+105.18% 67.82B
-0.41%-2.30%+33.53%+78.63% 63.22B
-1.11%+2.78%-14.86%+375.59% 27.58B
-4.92%-3.22%-3.90%-17.87% 26.06B
+0.45%+0.65%+31.60%+16.07% 25.38B
+1.12%+0.84%+24.50%-17.84% 19.89B
+6.04%+7.25%+233.25%+383.12% 17.4B
+0.78%-0.24%-6.06%+529.71% 14.95B
-2.27%+1.37%+53.01%+160.83% 14.62B
Average -0.00%+1.67%+53.79%+159.78% 27.72B
Weighted average by Cap. +0.26%+0.45%+37.83%+140.63%

Financials

2026 *2027 *
Net sales 108M 93.03M 87.52M 79.87M 149M 10.26B 150M 1.04B 401M 5.24B 406M 397M 16.68B 90.61M 77.9M 73.29M 66.88M 125M 8.59B 125M 868M 336M 4.39B 340M 333M 13.97B
Net income -88.7M -76.27M -71.75M -65.48M -122M -8.41B -123M -850M -329M -4.3B -333M -326M -13.68B -138M -119M -112M -102M -190M -13.09B -191M -1.32B -512M -6.69B -519M -507M -21.29B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
08/09/26 US$4.320 -1.82% 419,585
04/09/26 US$4.400 +3.53% 442,785
03/09/26 US$4.250 -1.62% 478,599
02/09/26 US$4.320 +6.93% 581,703
01/09/26 US$4.040 +1.25% 499,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.320USD
Average target price
8.000USD
Spread / Average Target
+85.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!